Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 5
2010 7
2011 14
2012 11
2013 20
2014 53
2015 118
2016 131
2017 160
2018 162
2019 213
2020 224
2021 265
2022 247
2023 273
2024 121

Text availability

Article attribute

Article type

Publication date

Search Results

1,837 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with ninted …
In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbat …
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN. Lamb YN. Drugs. 2021 Apr;81(5):575-586. doi: 10.1007/s40265-021-01487-0. Epub 2021 Mar 25. Drugs. 2021. PMID: 33765296 Free PMC article. Review.
Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. ...The most common adverse even …
Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had …
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. Wind S, et al. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0. Clin Pharmacokinet. 2019. PMID: 31016670 Free PMC article. Review.
Sex and renal function have no influence on nintedanib pharmacokinetics, while effects of ethnicity, low body weight, older age and smoking are within the inter-patient variability range of nintedanib exposure and no dose adjustments are required. ...Concomitant tre …
Sex and renal function have no influence on nintedanib pharmacokinetics, while effects of ethnicity, low body weight, older age and s …
Nintedanib.
[No authors listed] [No authors listed] 2023 Dec 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Dec 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643465 Free Books & Documents. Review.
Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during nintedanib therapy are not uncommon and multiple instances of acute li …
Nintedanib is an orally available tyrosine kinase receptor antagonist that inhibits collagen formation and is used to treat idiopathi …
Nintedanib.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999921 Free Books & Documents. Review.
No information is available on the clinical use of nintedanib during breastfeeding. Because nintedanib is more than 97% bound to plasma proteins, the amount in milk is likely to be low. ...The manufacturer recommends that breastfeeding be discontinued during nint …
No information is available on the clinical use of nintedanib during breastfeeding. Because nintedanib is more than 97% bound …
Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Flaherty KR, Brown KK, Dumistracel M, Erhardt E, Bertulis J, Gahlemann M, Stowasser S, Griese M; InPedILD trial investigators. Deterding R, et al. Eur Respir J. 2023 Feb 2;61(2):2201512. doi: 10.1183/13993003.01512-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36041751 Free PMC article. Clinical Trial.
The primary objectives of the InPedILD trial were to determine the dose-exposure and safety of nintedanib in children and adolescents with fibrosing ILD. METHODS: Patients aged 6-17 years with fibrosing ILD on high-resolution computed tomography and clinically significant …
The primary objectives of the InPedILD trial were to determine the dose-exposure and safety of nintedanib in children and adolescents …
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Wollin L, et al. Eur Respir J. 2019 Sep 19;54(3):1900161. doi: 10.1183/13993003.00161-2019. Print 2019 Sep. Eur Respir J. 2019. PMID: 31285305 Free PMC article. Review.
This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patients with progressive fibrosing ILDs other than IPF (INBUILD) will report results in 2019....
This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis. A trial of nintedanib in patient …
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J, Xu H, Ma L, Li C, Qin W, Chen X, Yi M, Sun L, Liu B, Yuan X. Tu J, et al. Theranostics. 2022 Jan 1;12(2):747-766. doi: 10.7150/thno.65828. eCollection 2022. Theranostics. 2022. PMID: 34976211 Free PMC article.
Moreover, our results showed an increased expression of PD-L1 and promoted phosphorylation of STAT3 after nintedanib (1 M) treatment. Conclusion: The combination of nintedanib and alphaPD-L1 increased ICI therapy responses, relieved lung complications and further ac …
Moreover, our results showed an increased expression of PD-L1 and promoted phosphorylation of STAT3 after nintedanib (1 M) treatment. …
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Finnerty JP, et al. BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1. BMC Pulm Med. 2021. PMID: 34895203 Free PMC article.
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus p …
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibros …
Nintedanib for Idiopathic Pulmonary Fibrosis.
Tepede A, Yogaratnam D. Tepede A, et al. J Pharm Pract. 2019 Apr;32(2):199-206. doi: 10.1177/0897190017735242. Epub 2017 Oct 10. J Pharm Pract. 2019. PMID: 29017422 Review.
Diarrhea was the most common adverse effect associated with nintedanib use. Outside of these clinical trials, there are limited data evaluating nintedanib for the treatment of IPF. ...Nintedanib slows IPF disease progression by reducing the rate of decline in …
Diarrhea was the most common adverse effect associated with nintedanib use. Outside of these clinical trials, there are limited data …
1,837 results